Medmix Forecast, price target & analysts
Medmix Target price 2026 - Analyst rating & recommendation
Medmix Classifications & Recommendation
Medmix Price Target
| Target Price | CHF15.71 |
| Price | CHF9.98 |
| Potential |
57.39%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Medmix 2027 .
The average Medmix target price is CHF15.71.
This is
57.39%
register free of charge
CHF16.80
68.34%
register free of charge
CHF13.64
36.62%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Medmix to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medmix stock has an average upside potential 2027 of
57.39%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million CHF | 448.00 | 452.42 |
| 7.42% | 0.99% | |
| EBITDA Margin | 18.59% | 20.28% |
| 11.91% | 9.07% | |
| Net Margin | 1.43% | 4.19% |
| 193.42% | 193.30% |
5 Analysts have issued a sales forecast Medmix 2026 . The average Medmix sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Medmix EBITDA forecast 2026. The average Medmix EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Medmix Analysts have issued a net profit forecast 2026. The average Medmix net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 0.15 | 0.47 |
| 183.33% | 213.33% | |
| P/E | 21.36 | |
| EV/Sales | 1.38 |
Current Medmix Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jun 24 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Mar 02 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Nov 25 2025 |
| RESEARCH PARTNERS AG |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jun 24 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jun 23 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Mar 02 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Nov 25 2025 |
|
Locked
RESEARCH PARTNERS AG:
Locked
➜
Locked
|
Feb 26 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
